Does doxepin cause weight loss

72 Stars Star This? /

Source: Circulation | Posted 16 years ago

    Tags:

| Email This |

Weight gain associated with antidepressant use can lead to patient non-compliance with therapy. Understanding which antidepressants can result in weight gain is, therefore, important for practitioners.

In their recent article, Rashmi Deshmukh, MD, and Kathleen Franco, MD, Department of Psychiatry and Psychology, Cleveland Clinic, Ohio, United States, reviewed the various classes of antidepressants and their effects on weight gain.

Irreversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, isocarboxazid, and tranylcypromine typically cause weight gain when used for less than 6 months or on a long-term basis, the authors write, while reversible MAOIs are less likely to cause weight gain, although they are not currently available in the United States.

Tricyclic antidepressants are likely to cause weight gain with both short-term and long-term use, the researchers continue, primarily because they increase appetite. Furthermore, the tertiary tricyclic drugs — such as amitriptyline, imipramine, and doxepin — are more likely to cause weight gain than secondary tricyclics because they are stronger histamine blockers.

In contrast, selective serotonin reuptake inhibitors (SSRIs) are not likely to cause weight gain if used for 6 months or less, although paroxetine may be more likely than other SSRIs to cause weight gain. Whether SSRIs cause weight gain when used for 1 year or longer is still under debate.

“Weight change induced by SSRIs is probably related to alteration in serotonin 2C receptor activity, appetite increase, carbohydrate craving, or recovery from clinical depression,” the researchers note.

For long-term therapy, nefazodone, a phenylpiperazine with selective serotonin and norepinephrine reuptake inhibition, is less likely than SSRIs and tricyclic compounds to cause weight gain, whereas bupropion “is essentially devoid of antihistaminic effects and is commonly associated with weight loss,” the authors note. “For long-term therapy, is less likely than SSRIs to cause weight gain,” they add.

To help manage weight gain, the researchers recommend educating patients about this possible side effect, and preventing weight gain by recommending exercise and caloric restriction. Clinicians can also consider switching patients to another antidepressant drug or adding another agent, such as a stimulant or an H2 receptor agonist to therapy.

“In our practice, we have found that adding low-dose bupropion (100 to 150 mg/day) or topiramate (25 to 50 mg/day) may help weight loss when used in addition to diet control and exercise,” the authors write.

72 Stars Star This? /

Low-dose doxepin (3 and 6 mg) for the treatment of insomnia

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

  • 1 Ancoli-Israel S, Roth T: Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep22,S347–S353 (1999).Medline, Google Scholar
  • 2 Ohayon MM: Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev.6,97–111 (2002).Crossref, Medline, Google Scholar
  • 3 Vitiello MV: Sleep disorders and aging: understanding the causes. J. Gerontol. A Biol. Sci. Med. Sci.52,M189–M191 (1997).Crossref, Google Scholar
  • 4 Riemann D: Insomnia and comorbid psychiatric disorders. Sleep Med.4,S15–S20 (2007).Crossref, Google Scholar
  • 5 Ford DE, Kamerow DB: Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA262,1479–1484 (1989).Crossref, Medline, CAS, Google Scholar
  • 6 Balter MB, Uhlenhuth EH: New epidemiologic findings about insomnia and its treatment. J. Clin. Psychiatry53,S34–S39 (1992).Medline, Google Scholar
  • 7 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th edition). American Psychiatric Association: Washington, DC, USA (2000).Google Scholar
  • 8 Hohagen F, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M: Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep17,551–554 (1994).Medline, CAS, Google Scholar
  • 9 Ohayon MM, Roth T: What are the contributing factors for insomnia in the general population? J. Psychosom. Res.51,745–755 (2001).Crossref, Medline, CAS, Google Scholar
  • 10 Benca RM, Ancoli-Isreal S, Moldofsky H: Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J. Clin. Psychiatry65,26–35 (2004).Medline, Google Scholar
  • 11 Stahl SM: Stahls Essential Psychopharmacology (3rd edition). Cambridge University Press, NY, USA (2008).Google Scholar
  • 12 Saper CB, Chou TC, Scammell TE: The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci.24,726–731 (2001).▪ Presents a thorough overview of the current understanding of the mechanisms that modulate sleep and wakefulness.Crossref, Medline, CAS, Google Scholar
  • 13 Ramelteon ORT: profile of a new sleep-promoting medication. Drugs Today42(4),255–263 (2006).Crossref, Medline, Google Scholar
  • 14 Brisbare-Roch C, Dingemanse J, Koberstein R et al.: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med.13(2),150–155 (2007).Crossref, Medline, CAS, Google Scholar
  • 15 Lu J, Greco MA: Sleep circuitry and the hypnotic mechanism of GABAA drugs. J. Clin. Sleep Med.2,S19–S26 (2006).Google Scholar
  • 16 Ebert B, Wafford KA, Deacon S: Treating insomnia: current and investigational pharmacological approaches. Pharmacol. Ther.112,612–629 (2006).Crossref, Medline, CAS, Google Scholar
  • 17 Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. Hum. Psychopharmacol.16,369–392 (2001).Crossref, Medline, CAS, Google Scholar
  • 18 Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamine. CNS Spectrums13,1027–1038 (2008).Crossref, Medline, Google Scholar
  • 19 Hill SJ, Ganellin CR, Timmerman H et al.: International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev.49(3),253–278 (1997).Medline, CAS, Google Scholar
  • 20 Steininger TL, Alam MN, Gong H et al.: Sleep-waking discharge of neurons in the posterior lateral hypothalamus in the albino rat. Brain Resl.840(1–2),138–147 (1999).Crossref, Medline, CAS, Google Scholar
  • 21 Nelson JC. Tricyclic and tetracyclic drugs. In: The American Psychiatric Publishing Textbook of Psychopharmacology. Schatzberg A, Nemeroff C (Eds). American Psychiatric Publishing, Washington, DC, USA, 207–230 (2004).Google Scholar
  • 22 Ayd FJ: Long-term treatment of chronic depression: 15-year experience with doxepin HCl. J. Clin. Psychiatry45(3),39–46 (1984).Medline, Google Scholar
  • 23 Burrows GD, Mowbray RM, Davies B: A sequential comparison of doxepin (Sinequan) and placebo in depressed patients. Med. J. Austr.1,364–366 (1972).Crossref, Medline, CAS, Google Scholar
  • 24 Ferguson JM, Mendels J, Manowitz NR: Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. J. Clin. Psychiatry55(6),258–263 (1994).Medline, CAS, Google Scholar
  • 25 Pinder RM, Brogden RN, Speight TM, Avery GS: Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs13,161–218 (1977).Crossref, Medline, CAS, Google Scholar
  • 26 Zonalon® (doxepin hydrochloride) cream, prescribing information. Bioglan Pharmaceuticals, PA, USA (2003).Google Scholar
  • 27 Roth T, Rogowski R, Hull S et al.: Efficacy and safety of doxepin 1, 3 and 6 mg in adults with primary insomnia. Sleep30,1555–1561 (2007).▪▪ Phase II dose–response crossover study determining the efficacy and safety of low-dose doxepin in adults with primary insomnia.Crossref, Medline, Google Scholar
  • 28 Scharf M, Rogowski R, Hull S et al.: Efficacy and safety of doxepin 1, 3 and 6 mg in elderly patients with primary insomnia. J. Clin. Psych.69,1557–1564 (2008).▪▪ Phase II dose–response crossover study determining the efficacy and safety of low-dose doxepin in elderly adults with primary insomnia.Crossref, CAS, Google Scholar
  • 29 Lankford A, Hull S, Mayleben D et al.: Efficacy and safety of doxepin 3 mg and 6 mg in adults with primary insomnia. Present at: The American Psychiatric Association’s 160th Annual Meeting. San Diego, CA, USA 19–24 May 2007.▪ Pivotal Phase III parallel-group study.Google Scholar
  • 30 Roth T, Durrence HH, Jochelson P et al.: Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med.11,843–847 (2010).Crossref, Medline, Google Scholar
  • 31 Lankford A, Segal S, Borders J et al.: Efficacy and safety of doxepin 6 mg in a 4-week outpatient trial of elderly adults with primary insomnia. Sleep31(Suppl.), (Abstract 0782) (2008).Google Scholar
  • 32 Krystal A, Durrence H, Scharf M et al.: Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep33,1553–1561 (2010).Crossref, Medline, Google Scholar
  • 33 Strecker RE, Nalwalk J, Dauphin LJ et al.: Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience113,663–670 (2002).Crossref, Medline, CAS, Google Scholar
  • 34 Ishizuka T, Yamamoto Y, Yamatodani A: The effect of orexin-A and -B on the histamine release in the anterior hypothalamus in rats. Neurosci. Lett.323,93–96 (2002).Crossref, Medline, CAS, Google Scholar
  • 35 Silenor® (doxepin), prescribing Information. Somaxon Pharmaceuticals, Inc., CA, USA; revised March (2010).Google Scholar
  • 36 Roth T, Zorick F, Wittig R et al.: The effects of doxepin HCl on sleep and depression. J. Clin. Psychiatry43,366–368 (1982).Medline, CAS, Google Scholar
  • 37 Hajak G, Rodenbeck A, Adler L et al.: Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry29,187–192 (1996).Crossref, Medline, CAS, Google Scholar
  • 38 Hajak G, Rodenbeck A, Voderholzer U et al.: Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J. Clin. Psychiatry62,453–463 (2001).Crossref, Medline, CAS, Google Scholar
  • 39 Rodenbeck A, Cohrs S, Jordan W et al.: The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. Psychopharmacology170,423–428 (2003).Crossref, Medline, CAS, Google Scholar
  • 40 Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T: Tolerance to daytime sedative effects of H1 antihistamines. J. Clin. Psychopharmacol.22,511–515 (2002).Crossref, Medline, CAS, Google Scholar
  • 41 Wechsler DA: Manual for the Wechsler Adult Intelligence Scale. The Psychological Corporation, NY, USA (1955).Google Scholar
  • 42 Lader M: Introduction to Psychopharmacology. Upjohn, MI, USA (1983).Google Scholar
  • 43 Bourin M, Briley M: Sedation, an unpleasant, undesirable, and potentially dangerous side-effect of many psychotropic drugs. Hum. Psychopharm.19,135–139 (2004).Crossref, Medline, CAS, Google Scholar
  • 44 Richtand NM, Woods SC, Berger SP, Strakowski SM: D3 dopamine receptor, behavioral sensitization and psychosis. Neurosci. Biobehav. Rev.25,427–443 (2001).Crossref, Medline, CAS, Google Scholar
  • 45 Richelson E: Psychotherapeutic drugs, histamine H1 and muscarinic acetylcholine receptors. Psychopharmacology and Biochemistry of Neurotransmitter Receptors. Roeske WR, Yamamura HI, Olsen RW, Usdin E (Eds). Elsevier, The Netherlands, 263–277 (1980).Google Scholar
  • 46 Preskorn SH, Flockhard D: 2006 Guide to Psychiatric Drug Interactions. Prim. Psychiatry13(4),35–64 (2006).Google Scholar
  • 101 National Heart, Lung and Blood Institute: Insomnia www.nhlbi.nih.gov/health/dci/Diseases/inso/inso_all.html (Accessed 24 August 2010)Google Scholar
  • 102 Hertzel L, Smith A: Census 2000 brief: the 65 years and over population: 2000 (Accessed 24 August 2010)Google Scholar
  • 103 National Sleep Foundation: Drowsy driving www.sleepfoundation.org/article/sleep-topics/drowsy-driving (Accessed 24 August 2010)Google Scholar
  • 104 National Sleep Foundation: Can’t sleep? What to know about insomnia www.sleepfoundation.org/article/sleep-related-problems/insomnia-and-sleep (Accessed 24 August 2010)Google Scholar
  • 105 National Sleep Foundation: Leading health organizations issue a ‘call to action’ to treat sleep as a vital sign of health. (2005) http://seniorjournal.com/NEWS/Aging/5-03-05InsomniaDay.htm (Accessed 24 August 2010)Google Scholar
  • 106 National Sleep Foundation. 2008 Sleep in American poll: summary of findings www.sleepfoundation.org/article/press-release/sleep-america-poll-summary-findings (Accessed 24 August 2010)Google Scholar

Sinequan

SIDE EFFECTS

NOTE: Some of the adverse reactions noted below have not been specifically reported with SINEQUAN use. However, due to the close pharmacological similarities among the tricyclics, the reactions should be considered when prescribing SINEQUAN (doxepin HCl).

Anticholinergic Effects

Dry mouth, blurred vision, constipation, and urinary retention have been reported. If they do not subside with continued therapy, or become severe, it may be necessary to reduce the dosage.

Central Nervous System Effects

Drowsiness is the most commonly noticed side effect. This tends to disappear as therapy is continued. Other infrequently reported CNS side effects are confusion, disorientation, hallucinations, numbness, paresthesias, ataxia, extrapyramidal symptoms, seizures, tardive dyskinesia, and tremor.

Cardiovascular

Cardiovascular effects including hypotension, hypertension, and tachycardia have been reported occasionally.

Allergic

Skin rash, edema, photosensitization, and pruritus have occasionally occurred.

Hematologic

Eosinophilia has been reported in a few patients. There have been occasional reports of bone marrow depression manifesting as agranulocytosis, leukopenia, thrombocytopenia, and purpura.

Gastrointestinal

Nausea, vomiting, indigestion, taste disturbances, diarrhea, anorexia, and aphthous stomatitis have been reported. (See Anticholinergic Effects.)

Endocrine

Raised or lowered libido, testicular swelling, gynecomastia in males, enlargement of breasts and galactorrhea in the female, raising or lowering of blood sugar levels, and syndrome of inappropriate antidiuretic hormone secretion have been reported with tricyclic administration.

Other

Dizziness, tinnitus, weight gain, sweating, chills, fatigue, weakness, flushing, jaundice, alopecia, headache, exacerbation of asthma, angle closure glaucoma, mydriasis and hyperpyrexia (in association with chlorpromazine) have been occasionally observed as adverse effects.

Withdrawal Symptoms

The possibility of development of withdrawal symptoms upon abrupt cessation of treatment after prolonged SINEQUAN administration should be borne in mind. These are not indicative of addiction and gradual withdrawal of medication should not cause these symptoms.

Read the entire FDA prescribing information for Sinequan (Doxepin)

Restoril (Oral)

Generic Name: temazepam (Oral route)

tem-AZ-e-pam

Medically reviewed by Drugs.com. Last updated on Feb 4, 2019.

  • Overview
  • Side Effects
  • Dosage
  • Professional
  • Interactions
  • More

Oral route(Capsule)

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options. Limit dosages and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation .

Commonly used brand name(s)

In the U.S.

  • Restoril

Available Dosage Forms:

  • Capsule

Therapeutic Class: Hypnotic

Pharmacologic Class: Benzodiazepine, Short or Intermediate Acting

Uses for Restoril

Temazepam is used to treat insomnia (trouble with sleeping). This medicine is for short-term (usually 7 to 10 days) use only. Temazepam is a benzodiazepine. Benzodiazepines belong to the group of medicines called central nervous system (CNS) depressants, which are medicines that slow down the nervous system.

This medicine is available only with your doctor’s prescription.

Before using Restoril

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of temazepam in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of temazepam in the elderly. However, elderly patients are more likely to have unwanted effects (eg, severe drowsiness, dizziness, confusion, clumsiness, or unsteadiness) and age-related kidney, liver, or heart problems, which may require caution and an adjustment in the dose for patients receiving temazepam.

Pregnancy

Pregnancy Category Explanation
All Trimesters X Studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. This drug should not be used in women who are or may become pregnant because the risk clearly outweighs any possible benefit.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

  • Flumazenil

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

  • Alfentanil
  • Amobarbital
  • Benzhydrocodone
  • Bromazepam
  • Bromopride
  • Buprenorphine
  • Butabarbital
  • Butalbital
  • Butorphanol
  • Carbinoxamine
  • Carisoprodol
  • Chloral Hydrate
  • Chlorzoxazone
  • Codeine
  • Dantrolene
  • Dihydrocodeine
  • Doxylamine
  • Ethchlorvynol
  • Fentanyl
  • Flibanserin
  • Fospropofol
  • Hydrocodone
  • Hydromorphone
  • Levorphanol
  • Lofexidine
  • Loxapine
  • Meclizine
  • Meperidine
  • Mephenesin
  • Mephobarbital
  • Meprobamate
  • Metaxalone
  • Methadone
  • Methocarbamol
  • Methohexital
  • Metoclopramide
  • Midazolam
  • Mirtazapine
  • Morphine
  • Morphine Sulfate Liposome
  • Nalbuphine
  • Oxycodone
  • Oxymorphone
  • Pentazocine
  • Pentobarbital
  • Periciazine
  • Phenobarbital
  • Primidone
  • Propofol
  • Secobarbital
  • Sodium Oxybate
  • Tapentadol
  • Thiopental
  • Tramadol
  • Zolpidem

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

  • Rifapentine
  • St John’s Wort
  • Theophylline

Interactions with food/tobacco/alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.

  • Ethanol

Other medical problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

  • Alcohol or abuse, or history of or
  • Breathing problems or lung disease or
  • Depression, history of or
  • Drug abuse or dependence, or history of or
  • Mental health problems, history of—Use with caution. May make these conditions worse.

  • Kidney disease or
  • Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

Proper use of Restoril

Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.

This medicine should come with a Medication Guide. Read and follow the instructions carefully. Ask your doctor if you have any questions.

Take temazepam just before going to bed, when you are ready to go to sleep. This medicine works very quickly to put you to sleep.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

  • For oral dosage form (capsules):
    • For insomnia (trouble sleeping):
      • Adults—15 milligrams (mg) at bedtime. Your doctor may adjust your dose if needed.
      • Older adults—At first, 7.5 mg at bedtime. Your doctor may adjust your dose if needed.
      • Children—Use and dose must be determined by your doctor.

Missed dose

If you miss a dose of this medicine, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Use this medicine only when you cannot sleep. You do not need to take it on a schedule.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions while using Restoril

It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly. Blood tests may be needed to check for any unwanted effects.

If your condition does not improve within 7 to 10 days, or if it becomes worse, check with your doctor.

Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.

This medicine may cause sleep-related behaviors such as driving a car (sleep-driving), walking (sleep-walking), having sex, making phone calls, or preparing and eating food while asleep or not fully awake. If these reactions occur, tell your doctor right away.

This medicine will add to the effects of alcohol and other central nervous system (CNS) depressants. CNS depressants are medicines that slow down the nervous system, which may cause drowsiness or make you less alert. Some examples of CNS depressants are antihistamines or medicine for hay fever, allergies, or colds, sedatives, tranquilizers, or sleeping medicine, prescription pain medicine or narcotics, barbiturates or medicine for seizures, muscle relaxants, or anesthetics (numbing medicines), including some dental anesthetics. This effect may last for a few days after you stop taking this medicine. Check with your doctor before taking any of the above while you are using this medicine.

This medicine may cause some people, especially older persons, to become drowsy, dizzy, lightheaded, clumsy or unsteady, or less alert than they are normally. Even though temazepam is taken at bedtime, it may cause some people to feel drowsy or less alert on arising. Also, this medicine may cause double vision or other vision problems. Make sure you know how you react to temazepam before you drive, use machines, or do anything else that could be dangerous if you are dizzy, or are not alert or able to see well.

If you develop any unusual and strange thoughts or behavior while you are taking temazepam, be sure to discuss it with your doctor. Some changes that have occurred in people taking this medicine are like those seen in people who drink alcohol and then act in a manner that is not normal. Other changes may be more unusual and extreme, such as confusion, worsening of depression, hallucinations (seeing, hearing, or feeling things that are not there), suicidal thoughts, and unusual excitement, nervousness, or irritability.

Do not stop taking this medicine without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This may help prevent a worsening of your condition and reduce the possibility of withdrawal symptoms, such as convulsions (seizures), hallucinations, stomach or muscle cramps, tremors, or unusual behavior.

If you think you or someone else may have taken an overdose of this medicine, get emergency help at once. Taking an overdose of temazepam or taking alcohol or other CNS depressants with temazepam may lead to breathing problems and unconsciousness.

Temazepam may cause serious allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash, itching, hives, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, tongue, mouth, or throat while you are using this medicine.

Restoril side effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Less common

  • False or unusual sense of well-being
  • fear or nervousness
  • mood or mental changes

Rare

  • Difficult or labored breathing
  • fast, irregular, pounding, or racing heartbeat or pulse
  • large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs
  • loss of appetite
  • loss of memory
  • nightmares
  • problems with memory
  • seeing, hearing, or feeling things that are not there
  • shakiness and unsteady walk
  • tightness in the chest
  • uncontrolled eye movements
  • unsteadiness, trembling, or other problems with muscle control or coordination
  • unusual excitement, nervousness, restlessness, or irritability
  • weight loss

Incidence not known

  • Muscle cramps
  • seizures
  • shakiness in the legs, arms, hands, or feet
  • stomach cramps
  • sweating
  • trembling or shaking of the hands or feet
  • vomiting

Get emergency help immediately if any of the following symptoms of overdose occur:

Symptoms of overdose

  • Blurred vision
  • change in consciousness
  • confusion
  • decreased or absent reflexes
  • difficult or troubled breathing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • irregular, fast, slow, or shallow breathing
  • loss of consciousness
  • pale or blue lips, fingernails, or skin
  • sleepiness or unusual drowsiness
  • unusual tiredness or weakness

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Diarrhea
  • dry mouth
  • feeling of constant movement of self or surroundings
  • headache
  • nausea
  • sensation of spinning
  • unusual dullness or feeling of sluggishness

Rare

  • Backache
  • burning eyes

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Copyright 2019 Truven Health Analytics, Inc. All Rights Reserved.

Medical Disclaimer

More about Restoril (temazepam)

  • Side Effects
  • During Pregnancy or Breastfeeding
  • Dosage Information
  • Drug Images
  • Drug Interactions
  • Compare Alternatives
  • Support Group
  • Pricing & Coupons
  • En Español
  • 82 Reviews
  • Generic Availability
  • Drug class: benzodiazepines
  • FDA Alerts (1)

Consumer resources

  • Restoril

Professional resources

  • Restoril (AHFS Monograph)
  • … +1 more

Related treatment guides

  • Insomnia

6 Psychiatric Medications That May Make You Gain Weight

I had been on the drug Zyprexa (olanzapine) for four weeks and had already gained 15 pounds which, you know, didn’t help my depression. After going to a wedding and catching a side view of myself, I called my doctor and told him that my name was now Violet Beauregarde, the gum chewer in “Charlie and the Chocolate Factory” who floats to the ceiling as blueberry balloon. Except that when I rose to the top of the room I was crying.

“The two most common questions that patients ask me are, ‘Will I become dependent on the medications?’ and ‘Will I gain weight?’” says Everyday Health contributor Sanjay Gupta, M.D in a Johns Hopkins Depression and Anxiety Bulletin. It’s a serious concern for people considering taking any kind of psychiatric medicine, and a sensitive subject among patients who are currently on meds. “A rapidly expanding waistline is one of the major reasons why patients prematurely discontinue an otherwise effective treatment, fall back into depression, and experience a poor outcomes,” says Gupta.

He ranks various drugs for weight-gain potential and comes up with these six (in order of waist busters):

A few important points:

  • Clazaril, Seroquel, and Zyprexa are antipsychotic medications that increase insulin resistance, and therefore lead to weight gain.
  • Remeron is an alpha-2 receptor blocker, an antidepressant that is sometimes administered to people—emaciated folks–who need to gain weight. One set of studies indicated that most patients gain weight on Remeron after the first four weeks of treatment.
  • Depakote is an acidic chemical compound used as an anticonvulsant and mood-stabilizing drug to treat bipolar disorder.
  • Paxil is an SSRI more likely than any other SSRI to put on pounds, especially when used for a year or longer. One study indicated that 25 percent of Paxil users gained some serious weight compared with 7 percent of Prozac users and 4 percent of Zoloft users.
  • Among the older antidepressants, the tricyclics such as Sinequan (doxepin), Tofranil (imipramine), and Pemelor (nortriptyline) can cause short- and long-term weight.
  • Monoamine oxidase inhibitors (MAOIs) such as Nardil (phenelzine), Parnate (tranylcypromine), and Marplan (isocarboxazid) may also necessitate a new wardrobe.

That’s the bad news. And boy is it bad news. Have a weight loss or weight maintenance plan ready to go.

The good news is these drugs are peculiar. A compound that makes my sister’s pants split doesn’t do anything to me. And what makes me shriek at a side view in the mirror is easy on her metabolism. Even though we’re twins. So it’s just a painful trial and error – like everything in recovery – until you find the right drug that will help you function through the day AND allow you to pull on your jeans up without help.

Join Therese Borchard at one of three free private screenings of “Happy,” a film that explores what makes us happy, plus a discussion on depression and happiness, and a book signing. The events, which are produced in partnership with Everyday Health and funded by an advertising sponsor, are in Washington, D.C. (May 21), New York City (May 22), and Chicago (May 30).

Subscribe to Sanity Break

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *